RARE vs TOVX · rev $350.0M vs rev $300.0K
Ultragenyx (RARE) versus Theriva Biologics Inc. (TOVX) — a side-by-side from cached financials, not a winner call.
Ultragenyx (RARE) is a biotechnology company listed on US.
Theriva Biologics Inc. (TOVX) is a biotechnology company listed on NYSE MKT.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
Latest reported TOVX revenue for 2026-06-30 was $300.0K. Net income was -$5.3M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. TOVX currently screens at market cap $12.4M.
RARE currently screens at market cap $2.79B. TOVX currently screens at market cap $12.4M.
Not investment advice. Open the RARE and TOVX stock pages for the full models.
Not investment advice.